conoGenetix has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Our most advanced drug candidate is cgtx-544 which is a best-in-class Kv1.3 blocker for treatment of autoimmune diseases.
The company is well positioned to expand its range of class-leading ion channel blockers by targeting additional potassium, sodium, calcium and chloride channels, which will lead to other clinical applications in pain management and oncology.
GSV is a San Diego based venture capital company that provides capital, management and advisory services to early stage companies with disruptive technologies that can improve healthcare or create a more sustainable environment.
BioM is a venture fund by the Bavarian local government that offers young biotech companies extensive customized assistance along the road towards a successful existence. As an independent financing facility, BioM manages a seed fund and invests in young biotech companies in the Munich area.
Mey Capital Matrix GmbH is a Munich-based venture capital company.
The Company received several grants from federal or regional programs including:
m4 Leading Edge Cluster